NASDAQ:ANAB - AnaptysBio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $73.33 +1.98 (+2.78 %) (As of 05/24/2019 08:00 AM ET)Previous Close$71.35Today's Range$69.90 - $73.5952-Week Range$54.26 - $110.00Volume252,300 shsAverage Volume255,900 shsMarket Capitalization$1.98 billionP/E RatioN/ADividend YieldN/ABeta2.16 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California. Receive ANAB News and Ratings via Email Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANAB Previous Symbol CUSIPN/A CIK1370053 Webhttp://www.anaptysbio.com/ Phone858-362-6295Debt Debt-to-Equity RatioN/A Current Ratio17.05 Quick Ratio17.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5 million Price / Sales396.33 Cash FlowN/A Price / Cash FlowN/A Book Value$17.32 per share Price / Book4.23Profitability EPS (Most Recent Fiscal Year)($2.50) Net Income$-61,660,000.00 Net MarginsN/A Return on Equity-15.79% Return on Assets-14.99%Miscellaneous Employees78 Outstanding Shares27,024,000Market Cap$1.98 billion Next Earnings Date8/6/2019 (Estimated) OptionableOptionable AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions What is AnaptysBio's stock symbol? AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB." How were AnaptysBio's earnings last quarter? AnaptysBio Inc (NASDAQ:ANAB) announced its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. View AnaptysBio's Earnings History. When is AnaptysBio's next earnings date? AnaptysBio is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for AnaptysBio. What price target have analysts set for ANAB? 11 brokerages have issued twelve-month target prices for AnaptysBio's stock. Their forecasts range from $84.00 to $153.00. On average, they expect AnaptysBio's stock price to reach $127.6364 in the next twelve months. This suggests a possible upside of 74.1% from the stock's current price. View Analyst Price Targets for AnaptysBio. What is the consensus analysts' recommendation for AnaptysBio? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AnaptysBio. What are Wall Street analysts saying about AnaptysBio stock? Here are some recent quotes from research analysts about AnaptysBio stock: 1. According to Zacks Investment Research, "AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. " (5/7/2019) 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our 12-month price target of $126/share is based on an equally weighted composite of (a) $90.5/share, as a 35x multiple of taxed and diluted FY32 GAAP EPS of $27.66 discounted back to and (b) an NPV of $161/share (discount rate 12.0%, growth rate 2.0%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biotechnology company." (12/20/2018) 3. Cantor Fitzgerald analysts commented, ". $140 price target. We think positive Dupixent phase 3 nasal polyp data from REGN (Neutral)/SNY (Not Covered) is an incremental positive for ANAB as it helps de-risk ANAB’s readout in this indication in 2H 2019. ANAB is also studying etokimab in chronic sinusitis with nasal polyps (CSwNP) and is guiding for phase 2 data in 2H19 (n=100, placebo controlled study). Because of the similarities in Dupixent and etokimab mechanisms of actions, we believe this should increase the likelihood of etokimab’s success in this study." (10/16/2018) Has AnaptysBio been receiving favorable news coverage? Media stories about ANAB stock have been trending positive recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AnaptysBio earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. Who are some of AnaptysBio's key competitors? Some companies that are related to AnaptysBio include Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA), Perrigo (PRGO), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Array Biopharma (ARRY), Nektar Therapeutics (NKTR), Amarin (AMRN), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), TESARO (TSRO) and Taro Pharmaceutical Industries (TARO). What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include IQIYI (IQ), Alibaba Group (BABA), Baidu (BIDU), Momo (MOMO), Baozun (BZUN), Editas Medicine (EDIT), JD.Com (JD), NVIDIA (NVDA), Align Technology (ALGN) and bluebird bio (BLUE). Who are AnaptysBio's key executives? AnaptysBio's management team includes the folowing people: Mr. Hamza Suria, Pres, CEO & Director (Age 43)Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)Prof. Marco Londei, Chief Medical Officer (Age 62)Mr. Eric J. Loumeau, Gen. Counsel (Age 56)Dr. Hemant Kumar, Sr. VP of Manufacturing When did AnaptysBio IPO? (ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? AnaptysBio's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Janus Henderson Group PLC (12.15%), BlackRock Inc. (6.69%), OppenheimerFunds Inc. (3.98%), Viking Global Investors LP (3.07%) and Federated Investors Inc. PA (2.40%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria, Holdings A/S Novo, Marco Londei, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio. Which institutional investors are selling AnaptysBio stock? ANAB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Janus Henderson Group PLC, Goldman Sachs Group Inc., Advisor Group Inc., BlackRock Inc., California State Teachers Retirement System, American International Group Inc. and California Public Employees Retirement System. Company insiders that have sold AnaptysBio company stock in the last year include Dominic Piscitelli, Hamza Suria and Marco Londei. View Insider Buying and Selling for AnaptysBio. Which institutional investors are buying AnaptysBio stock? ANAB stock was acquired by a variety of institutional investors in the last quarter, including Redmile Group LLC, Dimensional Fund Advisors LP, Viking Global Investors LP, FMR LLC, Federated Investors Inc. PA, Schonfeld Strategic Advisors LLC, Geode Capital Management LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for AnaptysBio. How do I buy shares of AnaptysBio? Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AnaptysBio's stock price today? One share of ANAB stock can currently be purchased for approximately $73.33. How big of a company is AnaptysBio? AnaptysBio has a market capitalization of $1.98 billion and generates $5 million in revenue each year. The biotechnology company earns $-61,660,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. AnaptysBio employs 78 workers across the globe. What is AnaptysBio's official website? The official website for AnaptysBio is http://www.anaptysbio.com/. How can I contact AnaptysBio? AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected] MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 262 (Vote Outperform)Underperform Votes: 180 (Vote Underperform)Total Votes: 442MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: How to Invest in Growth Stocks Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.